Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Comparison of dezocine and hydromorphone in post-cesarean epidural analgesia: a retrospective study.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Additional Information
- Source:
Publisher: BioMed Central Country of Publication: England NLM ID: 100968535 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2253 (Electronic) Linking ISSN: 14712253 NLM ISO Abbreviation: BMC Anesthesiol Subsets: MEDLINE
- Publication Information:
Original Publication: [London] : BioMed Central, 2001-
- Subject Terms:
- Abstract:
Competing Interests: Declarations. Ethics approval and consent to participate: This study was approved by the Ethics Review Committee of the Second Affiliated Hospital of the University of South China (approval number: 2024006). The requirement for informed consent was waived by the committee due to the retrospective design of the study and the use of de-identified patient data. All methods were conducted in accordance with relevant institutional and national guidelines. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.
Background: Postoperative pain management following cesarean delivery is essential for optimizing maternal recovery and reducing complications. Patient-controlled epidural analgesia (PCEA) is widely used; however, the choice of opioid remains debated due to variations in effectiveness and side effect profiles. This study aims to compare the analgesic effectiveness and adverse effects of dezocine and hydromorphone in PCEA regimens for cesarean delivery.
Methods: In this retrospective study, 1,582 parturients who underwent cesarean delivery under neuraxial anesthesia and received postoperative PCEA between March 2019 and July 2022 were reviewed. 755 patients received dezocine (Group D) and 827 received hydromorphone (Group H). All patients received 250 mg ropivacaine compounded with either 10 mg dezocine or 4 mg hydromorphone, diluted to 250 ml. Primary outcomes included analgesic effectiveness (assessed via VAS scores, PCEA bolus frequency, and rescue analgesia rates) and adverse effects (nausea/vomiting, pruritus, lower limb numbness and motor block).
Results: Baseline demographic characteristics were comparable between groups (P > 0.05). Both groups showed comparable analgesic effectiveness with no significant differences in VAS scores (P = 0.29), PCEA bolus usage (P = 0.36), or need for rescue analgesia (P = 0.18). However, Group D experienced significantly fewer adverse effects. The incidence of nausea/vomiting was 16.9% in Group D vs. 28.1% in Group H (P < 0.001), and pruritus occurred in 12.3% vs. 24.8% (P < 0.001), respectively. No significant difference was observed in the incidence of lower limb numbness (P = 0.33) or motor block as assessed by Bromage score(P = 0.41).
Conclusions: Dezocine and hydromorphone demonstrated comparable analgesic effectiveness when administered via patient-controlled epidural analgesia (PCEA) following cesarean delivery. However, dezocine was associated with a significantly lower incidence of opioid-related adverse effects, indicating that it may serve as a safer and more tolerable alternative for postoperative pain management in obstetric patients.
(© 2025. The Author(s).)
- References:
PLoS One. 2015 Aug 19;10(8):e0136091. (PMID: 26287536)
World J Clin Cases. 2024 Jul 16;12(20):4265-4271. (PMID: 39015894)
Front Pharmacol. 2022 Aug 04;13:962671. (PMID: 35991892)
J Anesth. 2024 Oct;38(5):650-655. (PMID: 38980398)
J Clin Anesth. 2024 Dec;99:111664. (PMID: 39442405)
World J Clin Cases. 2019 Oct 26;7(20):3237-3246. (PMID: 31667174)
J Pain Res. 2018 Dec 18;12:49-59. (PMID: 30588079)
J Clin Anesth. 2013 Aug;25(5):379-383. (PMID: 23965210)
Front Pharmacol. 2023 Jul 10;14:1150045. (PMID: 37492093)
BMJ Open. 2024 Nov 2;14(11):e071818. (PMID: 39488417)
Front Pharmacol. 2025 Apr 28;16:1586393. (PMID: 40356993)
Acta Biomed. 2008 Aug;79(2):92-105. (PMID: 18788503)
Addiction. 2018 Jul;113(7):1264-1273. (PMID: 29589873)
Anesthesiology. 2020 Jun;132(6):1382-1391. (PMID: 32251031)
PLoS One. 2020 May 26;15(5):e0233412. (PMID: 32453759)
Anesth Analg. 2016 Sep;123(3):690-7. (PMID: 26974022)
Curr Opin Anaesthesiol. 2023 Jun 1;36(3):288-292. (PMID: 36994740)
EClinicalMedicine. 2022 Dec 24;56:101787. (PMID: 36590790)
Biosci Rep. 2017 Jun 8;37(3):. (PMID: 28533424)
Sci Rep. 2024 Oct 21;14(1):24704. (PMID: 39433860)
Pak J Pharm Sci. 2018 Sep;31(5(Special)):2191-2195. (PMID: 30463811)
Cell Mol Biol (Noisy-le-grand). 2020 Jun 05;66(3):149-154. (PMID: 32538762)
Br J Anaesth. 2021 Nov;127(5):e154-e156. (PMID: 34420683)
BMC Anesthesiol. 2024 Feb 5;24(1):51. (PMID: 38317099)
Am J Obstet Gynecol. 2024 Mar;230(3S):S1128-S1137.e6. (PMID: 38193879)
J Cardiothorac Surg. 2021 Apr 21;16(1):102. (PMID: 33882970)
Pain Physician. 2024 Nov;27(8):469-478. (PMID: 39621972)
BMC Anesthesiol. 2024 Jan 30;24(1):41. (PMID: 38291353)
Br J Anaesth. 2020 Mar;124(3):e117-e130. (PMID: 31955857)
Acta Pharmacol Sin. 2022 Jul;43(7):1646-1657. (PMID: 34737418)
Pain Res Manag. 2019 Mar 03;2019:9054538. (PMID: 30944686)
- Grant Information:
2025JJ81022 Natural Science Foundation of Hunan Province; 2023JJ60353 Natural Science Foundation of Hunan Province; 2025JJ81005 Natural Science Foundation of Hunan Province; B202317018313 Health Research Project of Hunan Provincial Health Commission; 202217014497 Health Research Project of Hunan Provincial Health Commission
- Contributed Indexing:
Keywords: Cesarean; Dezocine; Hydromorphone; Patient-controlled epidural analgesia
- Accession Number:
0 (Analgesics, Opioid)
Q812464R06 (Hydromorphone)
VHX8K5SV4X (dezocine)
0 (Tetrahydronaphthalenes)
0 (Bridged Bicyclo Compounds, Heterocyclic)
- Publication Date:
Date Created: 20251119 Date Completed: 20251119 Latest Revision: 20251121
- Publication Date:
20251121
- Accession Number:
PMC12628867
- Accession Number:
10.1186/s12871-025-03472-6
- Accession Number:
41257623
No Comments.